The CHMP of the EMEA has recommended marketing authorisation for Takeda's pioglitazone/glimepiride [Tandemact] tablet.

Source: Inpharma, Volume 1, Number 1562, 2006-11-04 , pp. 22-22(1)

Publisher: Adis International

Keywords: Development-status; Pioglitazone/glimepiride, therapeutic use; Research-and-development; Takeda-Global-Research-and-Development-Center; Type-2-diabetes-mellitus, treatment

Document Type: Short communication

Publication date: 2006-01-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers